Biomarkers and Precision Medicine

Mechanism of Resistance / Sensitivity

Biomarkers - mechanism of resistance

With our fully characterized cell lines, Diag2Tec offers you the possibility to investigate drug resistance and associated mechanisms of action. We can search if there is a correlation between the sensitivity of cells to the therapeutic agent investigated and the mutational status of genes commonly involved in hematological malignancies. We can also investigate in our cell lines, a potential correlation of your therapeutic agent sensitivity with NFkB index, the molecular subgroup of patients, chromosomal abnormalities… In addition, we can compare Gene Expression Profiling of sensitive and resistant cells to the therapeutic agent treatment by SAM (Significance Analysis of Micro-arrays) and/or by LIMA analyses and with RNAseq data.

These studies allow to identify activated or modulated pathways following treatment with a given drug and to select other drugs that could be paired with the therapeutic agent investigated for the best synergistic combination therapies.

  • Our Panel of Cell lines, primary cells from patients
  • Genomic data, Molecular profiling
  • Reactome, Ingenuity software
  • SAM (Significance Analysis of Micro-arrays) and/or LIMA analysis
  • RNA seq and/or Mutation profiling of cell lines and or/primary cells with or w/o treatment.
  • Identification of mechanisms/patways involved in drug sensitivity/resistance
  • Investigation of the best combination of treatments
  • A Final Report
  • Raw data of genomic data
  • List of genes involved in pathways

Identification of Biomarkers

Identification of biomarkers

To identify biomarkers predictive of hematological cancer cells to a given drug, we use RNA seq and Exome seq data generated with cell lines and primary cells from patients treated with the drug. Then, we select genes deregulated by the inhibitor in the different conditions and genes associated with a prognostic value in patients (using our independent cohorts of patients with hematological malignancies). Finally, the identification of Biomarkers is constructed using our patented methodologies.

Biomarkers associated with cancer cells response to a given inhibitor treatment can be validated using assays in additional primary cells from patients with hematological malignancies.

  • Our Panel of Cell lines, primary cells from patients
  • Genomic data of cohorts of patients
  • Patented methodology
  • Identification of predictive biomarker with patented methodologies
  • Validation in primary cells from patients
  • A Final Report
  • List of genes and/or mutations

ADDRESS

Diag2Tec
Cap Omega, Rond-Point Benjamin Franklin
CS 39521
34960 Montpellier, France
Email: contact@diag2tec.com

BROCHURES